Table 2.
Efficacy of checkpoint inhibitors plus denosumab in 29 patients
| Nivolumab + ipilimumab + denosumab (N = 13) | PD-1-inhibitor + denosumab (N = 16) | Total (N = 29) | |
|---|---|---|---|
| Best overall response: no. (%) | |||
| Complete response | 2 (15%) | 3 (19%) | 5 (17%) |
| Partial response | 5 (39%) | 5 (31%) | 10 (35%) |
| Stable disease | 3 (23%) | 4 (25%) | 7 (24%) |
| Progressive disease | 3 (23%) | 4 (25%) | 7 (24%) |
| Objective response: no. (%) | 7 (54%) | 8 (50%) | |
| Median duration of response (months) | 10.2 | 12.5 | |
| Median (range) PFS (months) | 6 (0–24) | 6 (1–44) | |
| Median (range) OS (months) | NR | NR | |
| Sclerosis of bone metastases: no. (%) | 6 (46%) | 12 (75%) | 18 (62%) |